Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2022-08-08 |
地点
法国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05487235 |
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-08-04 |
地点
阿根廷
澳大利亚 巴西 加拿大 大韩民国 新西兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, GDC-1971, Omeprazole |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | 阶段
第三阶段
|
Date Added 2022-08-01 |
地点
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Pembrolizumab, WTX-124 |
标签
MSI-H/ MMRd
|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States 德国 大韩民国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
标签
MSS/ MMRp
|
| NCT ID NCT05464030 |
TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | 阶段
第 1 阶段
|
Date Added 2022-07-19 |
地点
California, United States
Rhode Island, United States Texas, United States 加拿大 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
M9140 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05438342 |
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis | 阶段
不适用
|
Date Added 2022-06-29 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Chemotherapy，checkpoint immunotherapy, targeted therapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05426005 |
TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-06-21 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cadonilimab |
标签
MSI-H/ MMRd
|
| NCT ID NCT05425940 |
TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | 阶段
第三阶段
|
Date Added 2022-06-21 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States 澳大利亚 比利时 法国 德国 香港 Hungary 大韩民国 新西兰 波兰 葡萄牙 新加坡 西班牙 台湾 泰国 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT05409417 |
TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | 阶段
第二阶段
|
Date Added 2022-06-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物
Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX |
标签
MSS/ MMRp
|
